PHIA Koninklijke Philips N.V.

Philips announces new imaging and workflow enhancements for KODEX-EPD cardiac imaging and mapping system to treat heart rhythm disorders

Philips announces new imaging and workflow enhancements for KODEX-EPD cardiac imaging and mapping system to treat heart rhythm disorders

August 26, 2020

  • New release combines faster, higher resolution imaging for Medtronic cryoablation procedures
  • KODEX-EPD system now installed at 40 sites worldwide with over 1500 patients treated

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new imaging and workflow enhancements for its novel KODEX-EPD cardiac imaging and mapping system. The system is now being used to treat patients with Atrial Fibrillation (AF), a common heart rhythm disorder, at 40 sites worldwide with over 1500 patients treated. The latest release includes improvements in imaging and mapping performance, as well as enhanced features to support cryoablation procedures.

Unlike traditional methods to image the heart during AF procedures such as CT and X-ray fluoroscopy, the KODEX-EPD system uses a combination of sensors attached to the body and catheters inside the heart to image the anatomy and properties of the heart, using innovative dielectric sensing technology. As a result, electrophysiologists can create detailed 3D views of the heart of a patient in as little as three minutes and navigate to the target location more easily and efficiently, with the required precision and without using radiation.

“The new release of the KODEX-EPD system represents a significant step forward in terms of image quality and workflow efficiency for AF procedures, as we continue to work towards our longer term goal of providing real-time therapy assessment,” said Marlou Janssen, General Manager Philips EPD Solutions. “By partnering with Medtronic and developing unique capabilities for cryoablation, we can give more physicians access to this truly innovative cardiac imaging and mapping system, and contribute to delivering efficient workflows with Medtronic’s best-in-class cryoablation therapy.”

Advances in the new release include faster, high-resolution imaging, improvements in mapping functionality and point density, as well as new visualization options such as ‘multi-chamber’ view to help understand the relative positions of adjacent chambers and ‘glass view’, which provides physicians with an improved perception of 3D catheter location and orientation within the heart. For cryoablation procedures, the KODEX-EPD system offers enhanced Occlusion assessment functionality with high accuracy and a simplified workflow [1].

“Using the KODEX-EPD imaging system’s ability to provide high resolution imaging,  revealing specific pulmonary vein morphologies, has allowed me to personalize my ablation approach in Medtronic cryoballoon procedures,” said Marcin Kowalski MD, Director of Electrophysiology at , US. “Using the two innovative technologies together has significant benefits for our patients.”

                              

“Combining the short procedure times of cryoablation with the real-time imaging capabilities of the KODEX-EPD system, we have been able to further improve our efficient lab workflow” said Professor Lukas Dekker, Electrophysiologist at in Eindhoven, the Netherlands. “Moreover, fluoroless imaging with the KODEX-EPD system may reduce the dependency on fluoroscopy and pre-procedural CTs and thus help to reduce X-ray exposure to patients and staff, which is important to us.”

The KODEX-EPD cardiac imaging and mapping system is commercially available in the US, Europe, and China. It is part of Philips’ unique portfolio of systems, smart devices, software and services in image-guided therapy, which combine to provide healthcare providers with sophisticated, procedure-oriented solutions. More information is available at .

[1] While using KODEX-EPD occlusion functionality, physicians should always refer to the applicable cryoballoon technical manual, published literature, and exercise their discretion to guide confirmation of pulmonary vein occlusion.

For further information, please contact:

Steve Klink

Philips Group Press Office

Tel:

Email:

Fabienne van der Feer

Philips Image Guided Therapy

Tel:

Email:

 

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .



 

Attachments

EN
26/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new...

MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new board member April 2, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Carla Goulart Peron, MD, Chief Medical Officer at Philips, has been appointed to the of the Medical Device Innovation Consortium (). Founded in 2012, MDIC is a unique public-private partnership that brings stakeholders across the medical device spectrum together with the US Food and Drug Administration () and other agency partners to help ensure patient access to medical device inn...

 PRESS RELEASE

FDA clears Philips AI solution that provides real-time guidance during...

FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair March 26, 2026 Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures, supporting treatment [2]DeviceGuide integrates with Philips Azurion image-guided therapy platform that combines imaging, real-time data and intelligent software within a unified workflow to support more consistent, efficient and confidently guided minimally invasive procedures Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA...

 PRESS RELEASE

Philips launches IntraSight Plus to simplify coronary interventions an...

Philips launches IntraSight Plus to simplify coronary interventions and advance precision care March 25, 2026 Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient careWith FDA clearance and CE marking, IntraSight Plus streamlines the workflow efficiency of minimally invasive coronary procedures and can enable system operation time savings up to 47% in both the USA and Europe Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technolog...

 PRESS RELEASE

Philips remains No. 1 in Medtech at European Patent Office and the lar...

Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant March 24, 2026 Philips ranks No. 1 among medical technology companies in the European Patent Office Technology Dashboard 2025, filing 1,289 patent applications with the EPO in 2025.Philips’ platform-based solutions integrate hardware, software, data and AI to address clinical, operational and everyday health challenges.Philips’ innovation improved the lives of 2 billion people in 2025, with the goal of improving 2.5 billion lives per year by 2030, including 400 million people in medically unde...

 PRESS RELEASE

Philips convenes the Annual General Meeting of Shareholders 2026

Philips convenes the Annual General Meeting of Shareholders 2026 March 23, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. As previously announced, the agenda includes: Proposal to appoint John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.Proposals to re-appoint Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch